CME / ABIM MOC / CE

Myelodysplastic Syndrome and Myeloproliferative Neoplasms

Authors: Elias J. Jabbour, MD; Guillermo Garcia-Manero, MD; Amer Zeidan, MBBS, MHS; John Mascarenhas, MD; Srdan Verstovsek, MD, PhD
CME / ABIM MOC / CE Released: 11/8/2022
Valid for credit through: 11/8/2023

Credits Available

Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.00 ABIM MOC points

Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), benign hematologic diseases, and other related conditions.

The goal of this activity is for learners to be better able to personalize treatment for patients with MDS and MPNs by integrating clinical trial data and evidence-based recommendations on novel therapies.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recent clinical trial data on treatment strategies for MDS and MPNs
Have greater competence related to
- Selecting evidence-based treatment for patients with MDS and MPNs
- Managing adverse events associated with current therapies for patients with MDS and MPNs
Demonstrate greater confidence in their ability to
- Personalize treatment for patients with MDS and MPNs

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Elias J. Jabbour, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Elias J. Jabbour, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Amgen; Bristol Myers Squibb Company; Genentech; Novartis; Pfizer; Takeda
Received grants for clinical research from: AbbVie; Amgen; Pfizer; Takeda

Guillermo Garcia-Manero, MD

Professor of Medicine
Chief, Section of Myelodysplastic Syndromes
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Guillermo Garcia-Manero, MD, has the following relevant financial relationships:
Received grants for clinical research from: AbbVie; APR; Astex; Bristol Myers Squibb Company; Curis; Genentech; Gilead; Novartis

Amer Zeidan, MBBS, MHS

Associate Professor of Internal Medicine (Hematology)
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Disclosures

Amer Zeidan, MBBS, MHS, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Acceleron; Agios; Amgen; Aprea; Astellas; BeyondSpring; Boehringer Ingelheim; Bristol Myers Squibb Company; Cardiff; Cardinal; Celgene; Daiichi Sankyo; Epizyme; Geron; Gilead; Incyte; Ionis; Janssen; Jazz; Kura; Novartis; Otsuka; Pfizer; SeaGen, Inc.; Syndax; Taiho; Takeda; Trovagene; Tyme
Received grants for clinical research from: AbbVie; ADC Therapeutics; Amgen; Aprea; Astex; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Company; Cardiff; Celgene; Incyte; Medimmune; Novartis; Otsuka; Pfizer; Takeda; Trovagene
Other: Travel support from: Cardiff; Novartis; Pfizer
Clinical trial committees for: AbbVie; Bristol Myers Squibb Company; Celgene; Geron; Gilead; Kura; Novartis

John Mascarenhas, MD

Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosures

John Mascarenhas, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Bristol Myers Squibb Company; Celgene; Constellation; CTI BioPharma; Galecto; Geron; Imago; Incyte; Kartos; Karyopharm; Novartis; PharmaEssentia; Roche
Received grants for clinical research from: AbbVie; Bristol Myers Squibb Company; Celgene; CTI BioPharma; Geron; Incyte; Merck; Novartis; PharmaEssentia; Roche

Srdan Verstovsek, MD, PhD

Professor of Medicine
Director, Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Srdan Verstovsek, MD, PhD, has the following relevant financial relationships:
Served as an advisor or consultant for: Bristol Myers Squibb Company; Celgene; Constellation; Incyte; Novartis; Sierra
Received grants for clinical research from: AstraZeneca; Blueprint; Celgene; CTI BioPharma; Genentech; Gilead; Incyte; Italfarmaco; Novartis; NS Pharma; PharmaEssentia; Promedior; Protagonist; Roche; Sierra

Editor

Heather P. Friedman, MPH

Medical Education Director, Medscape, LLC

Disclosures

Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) ( 0.100 CEUs) (Universal Activity Number: JA0007105-0000-22-357-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Myelodysplastic Syndrome and Myeloproliferative Neoplasms

Authors: Elias J. Jabbour, MD; Guillermo Garcia-Manero, MD; Amer Zeidan, MBBS, MHS; John Mascarenhas, MD; Srdan Verstovsek, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/8/2022

Valid for credit through: 11/8/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Advances in Newly Diagnosed Higher-Risk MDS

What's the latest news in novel agents and targeted therapies for frontline HR-MDS?
Guillermo Garcia-Manero, MD

Advances in MDS Management Following HMA Failure

Are venetoclax combinations, targeted therapies, and emerging agents changing the landscape for HMA-failure HR-MDS?
Amer Zeidan, MBBS, MHS

Optimizing the Use of JAK Inhibitors in the Management of Myelofibrosis

Which factors determine treatment selection of a JAK inhibitor for patients with myelofibrosis?
John Mascarenhas, MD

Novel Agents in Polycythemia Vera and Essential Thrombocythemia

How are recent approvals and emerging agents improving the outlook for PV and ET?
Srdan Verstovsek, MD, PhD

Learning Feedback Questions

Before you begin, please take this brief survey.

Page 1 of 7

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Elias J. Jabbour, MD

Guillermo Garcia-Manero, MD

Amer Zeidan, MBBS, MHS

John Mascarenhas, MD

Srdan Verstovsek, MD, PhD

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Myelodysplastic Syndrome and Myeloproliferative Neoplasms

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Elias J. Jabbour, MD

Guillermo Garcia-Manero, MD

Amer Zeidan, MBBS, MHS

John Mascarenhas, MD

Srdan Verstovsek, MD, PhD

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Myelodysplastic Syndrome and Myeloproliferative Neoplasms

Contents of This CME Activity

Advances in Newly Diagnosed Higher-Risk MDS

Advances in MDS Management Following HMA Failure

Optimizing the Use of JAK Inhibitors in the Management of Myelofibrosis

Novel Agents in Polycythemia Vera and Essential Thrombocythemia

Learning Feedback Questions